Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context.

"JA has received honoraria as a member of an advisory board and/or speaker from Sobi, BioMarin, Takeda, Novo Nordisk, Bayer, Roche, uniQure, Octapharma, Pfizer, Idogen and CSL Behring, research support to the institution from Bayer, Octapharma, Takeda, Pfizer, CSL Behring and Sobi/Biogen. FB has received honoraria as a member of an advisory board and/or speaker from Sobi, BioMarin, Takeda, Novo Nordisk, Bayer, Roche, uniQure, Octapharma, Pfizer, Idogen and CSL Behring. KS has received speaker fees from Octapharma, Sobi, Shire and Novo Nordisk and has been a scientific advisory board member for Novo Nordisk, Sobi and BioMarin. MFB has received honoraria as a member of an advisory board and speaker from Sobi, Takeda, Roche, and CSL Behring. Emma Engman Grahn has received honoraria as a member of an advisory board/consultant from BioMarin, CSL Behring, Sobi and Takeda. PK has received honoraria as a member of an advisory board and/or speaker from BioMarin, Novo Nordisk, uniQure, and CSL Behring. AEL has received honoraria as a member of an advisory board and/or speaker from Bayer, BioMarin, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Sobi and Takeda. PAH has received honoraria as a consultant for Bayer, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Takeda and Sobi and research support to the institution from Bayer, Octapharma, Pfizer, Takeda and Sobi. MM has received grants/research support as an investigator in clinical trials promoted by Sobi, Roche, Novo Nordisk, Octapharma, and honoraria as a member of an advisory board and/or speaker from Sobi, BioMarin, Pfizer and CSL Behring. KT and CH are stockholders and employees of BioMarin. PGT has no competing interests to disclose."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Medical writing assistance for this manuscript was funded by BioMarin."